Other equities research analysts also recently issued research reports about the company. Zacks Investment Research downgraded Proteon Therapeutics from a hold rating to a sell rating in a report on Thursday, January 11th. Robert W. Baird set a $3.00 price objective on Proteon Therapeutics and gave the company a hold rating in a report on Wednesday, March 14th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $3.38.
Shares of Proteon Therapeutics stock opened at $2.45 on Friday. The company has a market capitalization of $43.30, a P/E ratio of -1.16 and a beta of 1.67. Proteon Therapeutics has a twelve month low of $1.10 and a twelve month high of $2.85.
Proteon Therapeutics (NASDAQ:PRTO) last released its quarterly earnings data on Wednesday, March 14th. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.14. equities research analysts anticipate that Proteon Therapeutics will post -1.43 earnings per share for the current year.
An institutional investor recently raised its position in Proteon Therapeutics stock. Renaissance Technologies LLC boosted its holdings in Proteon Therapeutics Inc (NASDAQ:PRTO) by 17.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 201,500 shares of the biopharmaceutical company’s stock after acquiring an additional 29,600 shares during the period. Renaissance Technologies LLC owned 1.14% of Proteon Therapeutics worth $383,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 50.56% of the company’s stock.
WARNING: This piece was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thelincolnianonline.com/2018/03/19/hc-wainwright-analysts-give-proteon-therapeutics-prto-a-2-00-price-target.html.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.